{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-026931","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.726888+00:00","generated_at":"2026-05-17T07:23:01.803993+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Telomir reports preclinical data: Telomir-1 reactivates CDKN2A, beats rapamycin and chemo","bullets":["New data in PC3 human prostate cancer xenografts shows Telomir-1 inhibits DNA hypermethylation of CDKN2A.","Telomir-1 outperformed rapamycin and chemotherapy in reactivating the master tumor suppressor CDKN2A.","Findings build on prior STAT1 data, supporting Telomir-1 as a broad-spectrum DNA methylation reset therapy.","Company advancing pre-IND program with CMC and IND-enabling studies toward first IND submission."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-026931","json":"https://secwatch.observer/filing/0001641172-25-026931.json","markdown":"https://secwatch.observer/filing/0001641172-25-026931.md","text":"https://secwatch.observer/filing/0001641172-25-026931.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000164117225026931/0001641172-25-026931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000164117225026931/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:23:01.803993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}